Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Frontier Bio and Thermo Fisher to Collaborate on Novel HIV Candidate

publication date: Sep 26, 2019

Nanjing Frontier Bio will collaborate with Thermo Fisher Scientific to develop a novel treatment for human immunodeficiency virus (HIV), providing clinical trial supplies of the candidate. Frontier already has a China approved treatment for HIV, albuvirtide, but it is developing a second HIV treatment that it in-licensed from the Rockefeller University of New York City. Frontier's drug development is centered on a long-acting peptide platform designed to transform any peptide drug into a long-acting agent. More details....

Stock Symbol: (NYSE: TMO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.